17096 Federal Register / Vol. 87, No. 58 / Friday, March 25, 2022 / Notices 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

785. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of 

respondent 

Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hour 

Information Collection Questionnaire (Data Management System) (HWWTP, DOE).Grantee ......................... 25 2 14 700 

Information Collection Questionnaire (Survey) 

SBIR.

Grantee ......................... 85 1 1 85 

Total ............................................................... ....................................... 110 135 ........................ 785 

Jane M. Lambert, 

Project Clearance Liaison, National Institute 

of Environmental Health Sciences, National 

Institutes of Health. 

[FR Doc. 2022–06346 Filed 3–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Purity 

Specifications, Storage and Distribution of 

Medications Development (8961). 

Date: May 2, 2022. 

Time: 12:00 p.m. to 1:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5843, trinh.tran@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: March 21, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–06298 Filed 3–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIH Support for 

Conferences and Scientific Meetings (Parent 

R13 Clinical Trial Not Allowed). 

Date: April 27–29, 2022. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G53, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Konrad Krzewski, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G53, Rockville, MD 

20852, 240–747–7526, konrad.krzewski@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: March 21, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–06297 Filed 3–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2022–0203] 

Cooperative Research and 

Development Agreement—Beyond 

Visual Line of Sight (BVLOS) 

Technology for Coast Guard (CG) 

Unmanned Aircraft System (UAS) 

Operations 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of intent; request for 

comments. 

SUMMARY: The Coast Guard announces 

its intent to enter into a cooperative 

research and development agreement 

(CRADA) with companies to evaluate a 

detect and avoid (DAA) system to 

determine its potential use in a 

maritime environment to enable the 

Coast Guard to safely fly small UAS 

(SUAS) beyond visual line of sight 

(BVLOS). The Coast Guard will conduct 

flight testing and evaluations of SUAS 

DAA technology against CG mission 

scenarios. From our previous 

solicitations, the Coast Guard is 


lotter on DSK11XQN23PROD with NOTICES1